fda bpc 157 is reviewing seven peptides this week, BPC-157, MOTS-c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline Big news for the peptide

Can I eat the day of the procedure

Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose

The FDA noted similar observations at the company's Wisconsin site

Eligibility is determined by Live Vitals licensed providers